← Back to Search

CDK4/6 Inhibitor

Copanlisib + Usual Treatment for Advanced Breast Cancer

Winston-Salem, NC

Phase 1

Waitlist Available

Led By Cynthia X Ma

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >= 18 years

Washout from prior systemic anti-cancer therapy of at least 3 weeks from chemotherapy or 5 half-lives from oral targeted drugs, and treatment related adverse events recovered to grade 1 (except for alopecia) before the start of study treatment. Washout from prior radiation therapy of at least 2 weeks before the start of the study treatment. Washout from prior endocrine therapy is not required

Must not have

Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure (> New York Heart Association [NYHA] class 2), unstable angina pectoris, new-onset angina, uncontrolled hypertension despite optimal medical management, seizure disorder requiring medication, or psychiatric illness/social situations that would limit compliance with study requirements

Patients with non-healing wound, ulcer, or bone fracture not due to breast cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying the effects of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2 negative stage IV breast cancer.

See full description

Who is the study for?

This trial is for adults with hormone receptor positive, HER2 negative metastatic breast cancer. Participants must have recovered from previous treatments and agree to use contraception. They should not have had more than one chemotherapy in the metastatic setting or certain prior medications, and they can't join if they've had recent major surgeries, uncontrolled illnesses, or are pregnant.Check my eligibility

What is being tested?

The study tests adding copanlisib to fulvestrant and abemaciclib (usual therapy) for advanced breast cancer. It's a phase I/II trial aiming to see if this combination works better than the usual therapy alone by blocking enzymes that help tumor cells grow.See study design

What are the potential side effects?

Potential side effects include blood disorders, high blood sugar levels, fatigue, digestive issues like diarrhea or liver problems. There may also be risks of infection due to lowered immune function and possible heart-related side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

show original

Select...

I have not had cancer treatment for 3 weeks or the required time for my medication.

show original

Select...

My breast cancer is ER/PR positive, HER2 negative, and stage IV.

show original

Select...

My kidney function, measured by GFR, is at least 30 mL/min.

show original

Select...

I can take care of myself but might not be able to do heavy physical work.

show original

Select...

I had hepatitis C but am cured, or I'm being treated with no detectable virus.

show original

Select...

My hepatitis B virus load is undetectable with treatment.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have any severe illnesses like heart failure or uncontrolled high blood pressure that would stop me from following the study's requirements.

show original

Select...

I have a non-healing wound, ulcer, or bone fracture not caused by breast cancer.

show original

Select...

I haven't had serious bleeding issues in the last month.

show original

Select...

I have never had brain metastasis.

show original

Select...

I am allergic to certain cancer drugs similar to those used in this study.

show original

Select...

I am not taking certain strong medications that affect how my body processes the study drug.

show original

Select...

I haven't had major surgery or serious injury in the last 28 days, nor an open biopsy in the last 7 days.

show original

Select...

I have had major surgery on my stomach or intestines, or I have Crohn's, ulcerative colitis, or chronic diarrhea.

show original

Select...

I have been diagnosed with pheochromocytoma.

show original

Select...

My protein levels in urine are very high.

show original

Select...

I am not pregnant or breastfeeding.

show original

Select...

I have had a bone marrow or organ transplant from another person.

show original

Select...

I haven't had chemotherapy in the last 3 weeks or radiotherapy in the last 2 weeks.

show original

Select...

I haven't had a stroke, clot, or embolism in the last 3 months.

show original

Select...

I have a lung condition or severe breathing problems.

show original

Select...

I do not have a serious infection.

show original

Select...

I am not on immunosuppressive therapy.

show original

Select...

I do not have worsening brain metastases.

show original

Select...

I have a history of serious heart conditions, including fainting due to heart issues, dangerous irregular heartbeats, or sudden cardiac arrest.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Dose-limiting Toxicity (DLT)

Secondary study objectives

Clinical Benefit Rate

Objective Response Rate (ORR)

Overall Survival

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Phase I Part B Dose 1b (copanlisib, abemaciclib, fulvestrant)Experimental Treatment8 Interventions

Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1 and 15 and 100 mg abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive 500 fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.

Group II: Phase I Part A Dose 2 (copanlisib, abemaciclib, fulvestrant)Experimental Treatment8 Interventions

Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 and 150 mg abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive f500 mg fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.

Group III: Phase I Part A Dose 1 (copanlisib, abemaciclib, fulvestrant)Experimental Treatment8 Interventions

Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1 and 15 and 100 mg abemaciclib PO BID on days 2-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive 500 mg fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.

Group IV: Phase I Part B Dose 2b (copanlisib, abemaciclib, fulvestrant)Active Control8 Interventions

Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 and 100 mg abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive 500 mg fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Abemaciclib

2019

Completed Phase 2

~2120

Biopsy

2014

Completed Phase 4

~1210